7. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis.
2003(3):413–418.
8. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006(5):471–484.
9. Wilson HL, Dar A, Napper SK, Lopez MA, Babiuk LA, Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Int Rev Immunol. 2006(25):183–213.
10. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006(25):135–54.
11. Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev
Vaccines. 2007 (6):747–59.
12. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 2001(3):655–677.
13. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella
pertussis: role of IL-17-producing T cells. J Immunol. 2006: 177, 7980–7989.
14. Gold MC, Donnelly E, Cook MS, Leclair CM, Lewinsohn DA. Purified neonatal plasmacytoid dendritic cells overcome intrinsic
maturation defect with TLR agonist stimulation. Pediatr Res. 2006(60):34–37.
15. Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12 dependent Th-1 priming capacity
of neonatal dendritic cells. Immunity. 2006(22):467–477.
16. Tasker, Marshall-Clarke S. Functional responses of human neonatal B lymphocytes to antigen receptor cross-linking and
CpG DNA. Clin Exp Immunol. 2003(134):409–419.
17. Landers, CD, Bondada, S. CpG oligodeoxynucleotides stimulate cord blood mononuclear cells to produce immunoglobulins.
Clin Immunol. 2005(116):236–245.
18. De Wit D, Olislagers V, Goriely S, Vermeulen F, Wagner H, Goldman M, Willems F. Blood plasmacytoid dendritic cell responses
to CpG oligodeoxynucleotides are impaired in human newborns. Blood. 2004;103, 1030–1032.
19. Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P. Clinical effects of probiotics are associated
with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy. 2005(35):1557–1564.
20. Oppenheim JJ, Biragun A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity.
Ann Rheum Dis. 2003(62):17–21.
21. Bowdish DM, Davidson DJ, and Hancock, R.E. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol.
Immunol. 2006;306:27–66.
22. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol. 2006(18):24–30.
23. Mookherjee N, et al. Modulation of the TLT-mediated inflammatory response by the endogenous human host defense peptide
LL-37. J Immunol. 2006(176):2455–2464.
24. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim, JJ. Multiple roles of antimicrobial defensins, cathelicidins, and
eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004;22:(181–215).
25. Yang D, et al. Beta-defensins: Linking innate and adaptive immunity through dendritic and T-cell CCR6. Science. 1999(286):525–528.
26. Yang D, Chertov O, Oppenheim, JJ. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: Receptors
and activities of human defensins and cathelicidin (LL-37). J Leuko Biol. 2001(69):691–697.
|
